Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.

Bührer, Emanuel; D'Haese, David; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; Chovanec, Michal; ... (2024). Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium. European journal of cancer, 202(114042), p. 114042. Elsevier 10.1016/j.ejca.2024.114042

[img] Text
1-s2.0-S0959804924006981-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

AIMS

To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT).

PATIENTS AND METHODS

Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their primaries corrected for known prognostic factors. Progression-free survival (5y-PFS) and overall survival at 5 years (5y-OS) were estimated by the Kaplan-Meier method.

RESULTS

Among 6792 patients with metastatic testicular NSGCT, 3224 (47%) had TER in their primary, and 3568 (53%) did not. In the IGCCCG good prognosis group, the 5y-PFS was 87.8% in TER versus 92.0% in NTER patients (p = 0.0001), the respective 5y-OS were 94.5% versus 96.5% (p = 0.0032). The corresponding figures in the intermediate prognosis group were 5y-PFS 76.9% versus 81.6% (p = 0.0432) in TER and NTER and 5y-OS 90.4% versus 90.9% (p = 0.8514), respectively. In the poor prognosis group, there was no difference, neither in 5y-PFS [54.3% in TER patients versus 55.4% (p = 0.7472) in NTER], nor in 5y-OS [69.4% versus 67.7% (p = 0.3841)]. NSGCT patients with TER had more residual masses (65.3% versus 51.7%, p < 0.0001), and therefore received post-chemotherapy surgery more frequently than NTER patients (46.8% versus 32.0%, p < 0.0001).

CONCLUSION

Teratoma in the primary tumour of patients with metastatic NSGCT negatively impacts on survival in the good and intermediate, but not in the poor IGCCCG prognostic groups.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Beyer, Jörg

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1879-0852

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

08 Apr 2024 14:56

Last Modified:

21 Apr 2024 00:17

Publisher DOI:

10.1016/j.ejca.2024.114042

PubMed ID:

38564927

Uncontrolled Keywords:

Germ-cell tumours IGCCCG Non-seminoma Prognosis Teratoma

BORIS DOI:

10.48350/195564

URI:

https://boris.unibe.ch/id/eprint/195564

Actions (login required)

Edit item Edit item
Provide Feedback